Benzinga·2026-01-14 14:52Core Insights - U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 200 points on Wednesday [1] - TG Therapeutics Inc reported preliminary total global revenue for fiscal year 2025 of approximately $616 million, leading to a significant increase in its stock price [2] Company Performance - TG Therapeutics reported U.S. net product revenue for BRIUMVI of approximately $182 million for Q4 and $594 million for the full year, with these figures being unaudited [2] - TG Therapeutics shares surged by 11.6% to $31.10 following the revenue announcement [2] Other Notable Stock Movements - Rich Sparkle Holdings Ltd shares increased by 13.5% to $95.31 [3] - Cerus Corp gained 12.7% to $2.84 [3] - Clover Health Investments Corp saw an 11.2% rise to $2.82, driven by year-over-year membership growth in its Medicare Advantage PPO plans [3] - Highpeak Energy Inc shares rose by 8.3% to $5.07 [3] - Nutrien Ltd gained 7% to $65.62 after an upgrade from Morgan Stanley analyst Vincent Sinisi, with a price target increase from $70 to $77 [3]